Michael Dougherty

Foundation Medicine has appointed Michael Dougherty to its board of directors. He will fill an existing vacancy on the board and will initially join the board's audit committee. Dougherty most recently served as the executive chairman of Celator Pharmaceuticals, until its acquisition by Jazz Pharmaceuticals in July 2016. Previously, he served in a variety of senior positions, including chief operating officer of Genomics Collaborative, chief executive officer of Magainin Pharmaceuticals, and chief financial officer at Centocor.